A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Latest Information Update: 08 Nov 2023
At a glance
- Drugs Hyaluronic acid/triamcinolone (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Anika Therapeutics
- 08 Aug 2023 According to an Anika Therapeutics media release, company had a type-C meeting with the FDA in the second quarter and are actively engaging with them regarding next steps for U.S. regulatory approval.
- 28 Nov 2022 Status changed from active, no longer recruiting to completed.
- 01 Nov 2022 According to an Anika Therapeutics media release, the company will engage with the U.S. Food and Drug Administration (FDA) in the coming months on next steps for U.S. regulatory approval.